跳至主要内容
临床试验/NCT02352480
NCT02352480Unknown不适用

A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in All Wagner Grades of Diabetic Foot Ulcers

Nuo Therapeutics40 个研究点 分布在 1 个国家目标入组 760 人开始时间: 2015年1月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
760
试验地点
40
主要终点
Time to heal

研究概览

简要总结

The aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, randomized trial in which diabetic food ulcers (DFU) will be treated using Aurix plus Usual and Customary Care (UCC) and compared to a group receiving just UCC as provided in up to 100 U.S. wound centers

详细描述

Aurix is a platelet-rich plasma gel used in the treatment of non-healing chronic wounds. Prospective observational studies of the effectiveness of Aurix have demonstrated promising results in regard to the healing of DFUs, including severe Wagner grade 3 and 4 ulcers. The aim of this trial is to demonstrate the of complete wound healing in a prospective, open-label, randomized trial in which diabetic foot ulcers will be treated using Aurix to determine the time to heal at 12 weeks. Comparison will be made on a 1:1 basis of Aurix + UCC versus control subjects receiving undefined UCC.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Medicare eligible
  • ≥18 years of age
  • Type I or II diabetes requiring medical treatment as determined by the physician
  • The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (Index Ulcer) is a Wagner 1-5 DFU (see Appendix 9 for Wagner Classification) that is located on the dorsal, plantar, medial, or lateral aspect of the foot or heel (including all toe surfaces)
  • For subjects with potentially multiple eligible DFUs, the largest ulcer will be selected as the Index Ulcer for study. There must be at least 4 cm between the Index Ulcer and other ulcers; if all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure)
  • Debrided ulcer size between 0.5 cm2 and 50 cm2
  • Subject has received UCC care for ≥ 2 weeks at treating wound clinic
  • Demonstrated adequate offloading regimen
  • Duration ≥ 1 month at first visit
  • Subject must be willing to comply with the Protocol, which will be assessed by enrolling clinician.

排除标准

  • Subjects known to be sensitive to Aurix components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin
  • Presence of another wound that is concurrently treated and might interfere with treatment of the index wound by Aurix
  • Ulcer not of DFU pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology)
  • Patients on chemotherapeutic agents or any malignancy in the wound area
  • Subjects who are cognitively impaired
  • Serum albumin of less than 2.5 g/dL
  • Plasma Platelet count of less than 100 x 109/L
  • Hemoglobin of less than 10.5 g/dL
  • Subject has inadequate venous access for repeated blood draw required for Aurix administration.

研究组 & 干预措施

Aurix + UCC

Experimental

Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.

干预措施: Aurix (Device)

Usual and Customary Care

No Intervention

Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.

结局指标

主要结局

Time to heal

时间窗: 12 weeks

The primary endpoint of the trial is determine the time to heal diabetic foot ulcers treated with Aurix and Standard of Care at 12 weeks. Comparison will be made with the control arm of subjects treated only with Standard of Care.

次要结局

  • Incidence of amputations(12 weeks)
  • Proportion of completely healed ulcers(12 weeks)
  • W-QOL (Quality of life with chronic wounds) score(12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (40)

Loading locations...

相似试验

Effectiveness of Aurix Therapy in Diabetic Foot... | 临床试验